S.B. No. 670 is a legislative act aimed at granting patients the right to access investigational sun protection products that have completed phase one of clinical trials but have not yet received full approval from the U.S. Food and Drug Administration (FDA). The bill emphasizes the importance of patient autonomy in health decisions, allowing patients, in consultation with their physicians, to choose these products as a means to preserve their health. The act introduces Chapter 491 to the Health and Safety Code, which outlines definitions, eligibility criteria, informed consent requirements, and provisions for manufacturers regarding the distribution of these investigational products.

Key provisions include the requirement for physicians to provide written recommendations for eligible patients, the necessity of informed consent, and the stipulation that manufacturers are not obligated to provide these products but may do so at their discretion. Additionally, the bill protects physicians from disciplinary actions by the Texas Medical Board for recommending these products, provided they adhere to the medical standard of care. The act also ensures that state officials cannot obstruct patient access to investigational sun protection products. The bill is set to take effect immediately upon receiving a two-thirds vote from both houses or on September 1, 2025, if that threshold is not met.

Statutes affected:
Introduced: ()
Senate Committee Report: ()
Engrossed: ()
House Committee Report: ()
Enrolled: ()